VALL D’HEBRON INSTITUTE OF ONCOLOGY Preliminary results from a phase I clinical trial show that the first in class MYC inhibitor Omomyc (OMO-103) has few side effects, is tolerable, and stabilizes disease in some patients. Developed in-house by Laura Soucek’s Models of Cancer Therapies Group and VHIO-ICREA spin-off Peptomyc SL, OMO-103 targets the MYC oncogene...